Form 4: Director Pacala Boosts TOI Stake with RSU Grants

The Oncology Institute Director Mark L. Pacala acquired 81,790 shares of common stock through restricted stock unit grants.

Summary

• Director Mark L. Pacala of The Oncology Institute, Inc. (TOI) reported changes in his beneficial ownership.
• On November 20, 2025, Pacala acquired 46,296 shares of common stock in the form of restricted stock units (RSUs). These RSUs are scheduled to vest in full on the Issuer's 2026 annual stockholder meeting date, contingent on his continued service.
• On the same date, he also acquired an additional 35,494 shares of common stock, also as restricted stock units, which were fully vested upon grant.
• Both acquisitions were made at a price of $0 per share, typical for RSU grants.
• Following these transactions, Pacala's direct beneficial ownership of TOI common stock increased to 256,761 shares.

Sentiment

Score: 6

Explanation: The acquisition of shares by a director, even through grants, is generally a neutral to slightly positive signal as it increases their stake and aligns their interests with shareholders. The vesting schedule for a portion of the grants also indicates continued commitment.

Positives

• Director Mark L. Pacala increased his beneficial ownership by 81,790 shares through RSU grants, aligning his interests with shareholders.
• A portion of the grants (46,296 shares) is subject to future service, indicating continued commitment to the company.

Future Outlook

46,296 restricted stock units are scheduled to vest in full on the Issuer's 2026 annual stockholder meeting date, contingent on continued service with the Issuer.

Industry Context

This filing is a routine disclosure of insider ownership changes and does not provide broader industry context. It reflects standard compensation practices for directors in publicly traded companies, often involving equity grants to align interests with shareholders.

Related Party Transactions

• The restricted stock unit grants to Director Mark L. Pacala represent a form of compensation from the Issuer.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholder value due to increased equity ownership.
• Employees: No direct impact mentioned, but director's continued service commitment could indirectly benefit company stability.

Next Steps

• Vesting of 46,296 restricted stock units on The Oncology Institute's 2026 annual stockholder meeting date, subject to Mark L. Pacala's continued service.

Key Dates

Keywords

The Oncology Institute, TOI, Mark L. Pacala, Form 4, Insider Trading, Restricted Stock Units, RSU, Beneficial Ownership, Director Compensation